Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs.

Kimoto E, Mathialagan S, Tylaska L, Niosi M, Lin J, Carlo AA, Tess DA, Varma MVS.

J Pharmacol Exp Ther. 2018 Nov;367(2):322-334. doi: 10.1124/jpet.118.252049. Epub 2018 Aug 22.

PMID:
30135178
2.

A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 2: Prospectively Predicting Systemic and Liver Exposure in Healthy Subjects.

Li R, Kimoto E, Niosi M, Tess DA, Lin J, Tremaine LM, Di L.

Drug Metab Dispos. 2018 Apr;46(4):357-366. doi: 10.1124/dmd.117.078808. Epub 2018 Jan 12. Erratum in: Drug Metab Dispos. 2018 Apr;46(4):484.

PMID:
29330219
3.

A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects.

Li R, Niosi M, Johnson N, Tess DA, Kimoto E, Lin J, Yang X, Riccardi KA, Ryu S, El-Kattan AF, Maurer TS, Tremaine LM, Di L.

Drug Metab Dispos. 2018 Apr;46(4):346-356. doi: 10.1124/dmd.117.078790. Epub 2018 Jan 12. Erratum in: Drug Metab Dispos. 2018 Apr;46(4):483.

PMID:
29330218
4.

Selective Activation of AMPK β1-Containing Isoforms Improves Kidney Function in a Rat Model of Diabetic Nephropathy.

Salatto CT, Miller RA, Cameron KO, Cokorinos E, Reyes A, Ward J, Calabrese MF, Kurumbail RG, Rajamohan F, Kalgutkar AS, Tess DA, Shavnya A, Genung NE, Edmonds DJ, Jatkar A, Maciejewski BS, Amaro M, Gandhok H, Monetti M, Cialdea K, Bollinger E, Kreeger JM, Coskran TM, Opsahl AC, Boucher GG, Birnbaum MJ, DaSilva-Jardine P, Rolph T.

J Pharmacol Exp Ther. 2017 May;361(2):303-311. doi: 10.1124/jpet.116.237925. Epub 2017 Mar 13.

5.

Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach.

Mathialagan S, Piotrowski MA, Tess DA, Feng B, Litchfield J, Varma MV.

Drug Metab Dispos. 2017 Apr;45(4):409-417. doi: 10.1124/dmd.116.074294. Epub 2017 Feb 8.

6.

Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.

Bandara N, Zheleznyak A, Cherukuri K, Griffith DA, Limberakis C, Tess DA, Jianqing C, Waterhouse R, Lapi SE.

Mol Imaging Biol. 2016 Feb;18(1):90-8. doi: 10.1007/s11307-015-0861-5.

7.

Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide.

Robinson RP, Bartlett JA, Bertinato P, Bessire AJ, Cosgrove J, Foley PM, Manion TB, Minich ML, Ramos B, Reese MR, Schmahai TJ, Swick AG, Tess DA, Vaz A, Wolford A.

Bioorg Med Chem Lett. 2011 Jul 15;21(14):4150-4. doi: 10.1016/j.bmcl.2011.05.099. Epub 2011 Jun 2.

PMID:
21684740
8.

Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.

Lafontaine JA, Day RF, Dibrino J, Hadcock JR, Hargrove DM, Linhares M, Martin KA, Maurer TS, Nardone NA, Tess DA, Dasilva-Jardine P.

Bioorg Med Chem Lett. 2007 Sep 15;17(18):5245-50. Epub 2007 Jun 30.

PMID:
17632003
9.

A new chemical tool for exploring the physiological function of the PDE2 isozyme.

Chambers RJ, Abrams K, Garceau NY, Kamath AV, Manley CM, Lilley SC, Otte DA, Scott DO, Sheils AL, Tess DA, Vellekoop AS, Zhang Y, Lam KT.

Bioorg Med Chem Lett. 2006 Jan 15;16(2):307-10. Epub 2005 Nov 3.

PMID:
16275071
10.

A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.

Mylari BL, Armento SJ, Beebe DA, Conn EL, Coutcher JB, Dina MS, O'Gorman MT, Linhares MC, Martin WH, Oates PJ, Tess DA, Withbroe GJ, Zembrowski WJ.

J Med Chem. 2005 Oct 6;48(20):6326-39.

PMID:
16190759
11.

Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice.

Maurer TS, Debartolo DB, Tess DA, Scott DO.

Drug Metab Dispos. 2005 Jan;33(1):175-81. Epub 2004 Oct 22.

12.

Potent and selective, sulfamide-based human beta 3-adrenergic receptor agonists.

Dow RL, Paight ES, Schneider SR, Hadcock JR, Hargrove DM, Martin KA, Maurer TS, Nardone NA, Tess DA, DaSilva-Jardine P.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3235-40.

PMID:
15149682
13.

A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.

Mylari BL, Armento SJ, Beebe DA, Conn EL, Coutcher JB, Dina MS, O'Gorman MT, Linhares MC, Martin WH, Oates PJ, Tess DA, Withbroe GJ, Zembrowski WJ.

J Med Chem. 2003 Jun 5;46(12):2283-6.

PMID:
12773033
14.

Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs). Discovery of capromorelin.

Carpino PA, Lefker BA, Toler SM, Pan LC, Hadcock JR, Cook ER, DiBrino JN, Campeta AM, DeNinno SL, Chidsey-Frink KL, Hada WA, Inthavongsay J, Mangano FM, Mullins MA, Nickerson DF, Ng O, Pirie CM, Ragan JA, Rose CR, Tess DA, Wright AS, Yu L, Zawistoski MP, DaSilva-Jardine PA, Wilson TC, Thompson DD.

Bioorg Med Chem. 2003 Feb 20;11(4):581-90.

PMID:
12538023
15.

Discovery and biological characterization of capromorelin analogues with extended half-lives.

Carpino PA, Lefker BA, Toler SM, Pan LC, Hadcock JR, Murray MC, Cook ER, DiBrino JN, DeNinno SL, Chidsey-Frink KL, Hada WA, Inthavongsay J, Lewis SK, Mangano FM, Mullins MA, Nickerson DF, Ng O, Pirie CM, Ragan JA, Rose CR, Tess DA, Wright AS, Yu L, Zawistoski MP, Pettersen JC, DaSilva-Jardine PA, Wilson TC, Thompson DD.

Bioorg Med Chem Lett. 2002 Nov 18;12(22):3279-82.

PMID:
12392732
16.

Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data.

Kalvass JC, Tess DA, Giragossian C, Linhares MC, Maurer TS.

Drug Metab Dispos. 2001 Oct;29(10):1332-6.

17.

Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue.

Pan LC, Carpino PA, Lefker BA, Ragan JA, Toler SM, Pettersen JC, Nettleton DO, Ng O, Pirie CM, Chidsey-Frink K, Lu B, Nickerson DF, Tess DA, Mullins MA, MacLean DB, DaSilva-Jardine PA, Thompson DD.

Endocrine. 2001 Feb;14(1):121-32. Erratum in: Endocrine 2001 Apr;14(3):437.

PMID:
11322494
18.

First-pass metabolism and biliary recirculation of droloxifene in the female Sprague-Dawley rat.

Nickerson DF, Tess DA, Toler SM.

Xenobiotica. 1997 Mar;27(3):257-64.

PMID:
9141233
19.

Supplemental Content

Support Center